Brief: Health Canada Approves Nduvra (Tapinarof Cream)
14/04/2025 14:18
April 14 (Reuters) - Organon & Co OGN.N: HEALTH CANADA APPROVES NDUVRA™ (TAPINAROF CREAM), 1%, FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS Source text: ID:nCNWRcNcJa Further company coverage: OGN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Organon & Co.
See all newsIndia's Sun Pharma misses debt fundraise goal as investors demand higher yields, bankers say
Brief: Organon & Co Says It Does Not Expect To Record Milestone Expense In Q3 2026
India's Persistent Systems plans debut rupee debt sale to fund acquisition, bankers say
India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say
Organon & Co reports results for the quarter ended June 30 - Earnings Summary